Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Strober

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Journal of the American Academy of Dermatology|February 9, 2016
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Bruce E Strober, Robert Bissonnette, David Fiorentino, et al.
The New England Journal of Medicine|January 15, 2010
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasisChristopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, et al.
Journal of the American Academy of Dermatology|November 11, 2023
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)Richard B Warren, Lars E French, Andrew Blauvelt, et al.
Drug Safety|June 2, 2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLARRobert Bissonnette, Alice B Gottlieb, Richard G Langley, et al.
JAMA|August 25, 2011
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trialsCaitriona Ryan, Craig L Leonardi, James G Krueger, et al.
Dermatology and Therapy|December 4, 2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2Bruce E Strober, Jennifer Clay Cather, David Cohen, et al.
Dermatology and Therapy|December 4, 2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1Bruce E Strober, Jennifer Clay Cather, David Cohen, et al.
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
JAMA Dermatology|October 17, 2012
Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoidesStuart R Lessin, Madeleine Duvic, Joan Guitart, et al.
Dermatology and Therapy|December 23, 2018
Clinical Goals and Barriers to Effective Psoriasis CareBruce E Strober, Joelle M van der Walt, April W Armstrong, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Journal of the American Academy of Dermatology|February 9, 2016
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Bruce E Strober, Robert Bissonnette, David Fiorentino, et al.
The New England Journal of Medicine|January 15, 2010
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasisChristopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, et al.
Journal of the American Academy of Dermatology|November 11, 2023
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)Richard B Warren, Lars E French, Andrew Blauvelt, et al.
Drug Safety|June 2, 2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLARRobert Bissonnette, Alice B Gottlieb, Richard G Langley, et al.
JAMA|August 25, 2011
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trialsCaitriona Ryan, Craig L Leonardi, James G Krueger, et al.
Dermatology and Therapy|December 4, 2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2Bruce E Strober, Jennifer Clay Cather, David Cohen, et al.
Dermatology and Therapy|December 4, 2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1Bruce E Strober, Jennifer Clay Cather, David Cohen, et al.
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
JAMA Dermatology|October 17, 2012
Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoidesStuart R Lessin, Madeleine Duvic, Joan Guitart, et al.
Dermatology and Therapy|December 23, 2018
Clinical Goals and Barriers to Effective Psoriasis CareBruce E Strober, Joelle M van der Walt, April W Armstrong, et al.
Pageof 9